EICHOR
● Not Yet Recruiting
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
Condition: Cough · Refractory Chronic Cough · Unexplained Chronic Cough · Sponsor: McMaster University
About this study
The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.
This description comes directly from the study's public registry record.
Talk to the study team
Imran Satia, MD PhD · 905-521-2100 · satiai@mcmaster.ca
Always discuss trial participation with your own doctor first.
Locations (5)
| Respiratory Clinical Trials Centre, University of Calgary | Calgary, Alberta, Canada | — |
| Respiratory Research Lab, McMaster University | Hamilton, Ontario, Canada | — |
| St Joseph's Health Care London | London, Ontario, Canada | — |
| Institut universitaire de cardiologie et de pneumologie de Quebec - University Laval | Québec, Quebec, Canada | — |
| Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke | Sherbrooke, Quebec, Canada | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07288528